Does Rallies show 13F holders for QNRX?

Yes. Rallies tracks hedge fund and 13F ownership data for QNRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is QNRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for QNRX. It does not provide personalized investment advice.

QNRX (Quoin Pharmaceuticals, Ltd. American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX) is a publicly traded Healthcare sector company. As of May 21, 2026, QNRX trades at $5.06 with a market cap of $11.11M and a P/E ratio of 0.00. QNRX moved +0.00% today. Year to date, QNRX is -64.84%; over the trailing twelve months it is -38.17%. Its 52-week range spans $4.80 to $54.95. Analyst consensus is strong buy with an average price target of $35.00. Rallies surfaces QNRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns QNRX stock?

Hedge funds tracked by Rallies that own QNRX include Renaissance Technologies and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Quoin Pharmaceuticals, Ltd. American Depositary Shares.

QNRX Key Metrics

Key financial metrics for QNRX
Metric	Value
Price	$5.06
Market Cap	$11.11M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$54.95
52-Week Low	$4.80
Volume	10
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-15.80M
Gross Margin	0.00%

Top Hedge Funds Holding QNRX

Renaissance Technologies holds 133.12K shares of QNRX, changed +244.06% as of Dec 31, 2024.
Two Sigma holds 52.53K shares of QNRX, changed +64.90% as of Dec 31, 2024.

Latest QNRX News

Quoin Pharmaceuticals Earns FDA Fast Track, MHLW Orphan Designations, Targets 2027 NDA — May 7, 2026
Quoin Pharmaceuticals Plans Q3 2026 QRX009 Trials in Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex — Apr 28, 2026
Quoin Raises $104.5M, Gains Orphan and Fast Track Designations for QRX003 — Mar 26, 2026

Recent QNRX Insider Trades

LANGER DENNIS bought 15.15K (~$128.64K) on Oct 14, 2025.
Carter Denise P. bought 555.56K (~$250.00K) on Dec 23, 2024.
Myers Michael bought 555.56K (~$250.00K) on Dec 23, 2024.

QNRX Analyst Consensus

3 analysts cover QNRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.00.

Common questions about QNRX

Who owns QNRX stock?: Hedge funds tracked by Rallies that own QNRX include Renaissance Technologies and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Quoin Pharmaceuticals, Ltd. American Depositary Shares.
Does Rallies show 13F holders for QNRX?: Yes. Rallies tracks hedge fund and 13F ownership data for QNRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is QNRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for QNRX. It does not provide personalized investment advice.